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j ourna l homepage: www.eb iomed ic ine.comEditorialNovel Therapies for Heart FailureFebruary is chosen by both the American Heart Association and Brit-
ish Heart Foundation as the month for heart awareness, and we dedi-
cate this month's editorial to heart failure (HF) — a common and
debilitating condition in which unmet medical needs remain globally.
HF is a leading cause of hospitalization in people over 65 years of age,
andmore than half the patients diewithin 5 years of diagnosis. Hyperten-
sion is a key risk factor for HF andmany other heart conditions. Renin–an-
giotensin–aldosterone system (RAAS)-blockers and beta-blockers are the
cornerstone for hypertension and HF treatment, and they are among the
most widely prescribed classes of drugs worldwide. RAAS-blockers dilate
blood vessels while beta-blockers slow the heart rate, and together they
lower blood pressure and decrease oxygen demand from the heart. Land-
mark trials of RAAS- and beta-blockers have demonstrated these agents
to substantially reduce mortality in HF. Despite these existing therapies
for HF patients, readmission rates following hospital discharge remain
very high. HF prevalence is also on the rise with the aging population,
andmodern interventional strategies allowmore people to survive myo-
cardial infarction but develop HF eventually. As such, there is an urgent
need for next-generation HF therapeutics.
Unlike the ﬁeld of anti-thrombotic research that has achieved con-
siderable success in recent years with the regulatory approval of several
new oral anticoagulants and anti-platelet drugs, the research pipeline
for HF therapies look sparse with only a few promising candidatesmak-
ing it to the stage of clinical trials. Nevertheless, recent efforts to trans-
late scientiﬁc ﬁndings into practical tools for HF improvement have
started yielding fruit.
Neprilysin is ametalloprotease naturally expressed in awide variety
of tissues and is known since the late 1980s to degrade several vasoac-
tive peptides, the most important substrates being natriuretic peptides
(NPs). Overactivity of neprilysin occurs in some HF patients, and the
resulting reduction of NP levelsmay lead to vasoconstriction and hyper-
tension. Neprilysin inhibitors are thus being developed as potential an-
tihypertensive and HF drugs. LCZ696 is an investigational combination
drug consisting of valsartan (a RAAS-blocker) and the neprilysin inhib-
itor sacubitril— and the combination is often referred to as anARNi (an-
giotensin receptor-neprilysin inhibitor). Last year, results of the phase 3
clinical trial PARADIGM-HFwere published, comparing the efﬁcacy and
safety of LCZ696 versus enalapril (a RAAS-blocker) in chronic HF pa-
tients. LCZ696 showed a superior beneﬁt compared to enalapril, and
the trial is considered a major breakthrough in HF research. LCZ696 is
currently under expedited review by both the United States Food and
Drug Administration (FDA) and European Medicines Agency, and the
outcome is eagerly anticipated.
HF is characterized by a decreased cardiac output from an over-
loadedheart. Strategies to improve the heart's energy utilization, reduce
heart rate and oxygen demand, and increase stroke volume without
raising blood pressure are all taken into account when developing
novel HF therapies. Omecamtiv mecarbil is an investigational drughttp://dx.doi.org/10.1016/j.ebiom.2015.02.002
2352-3964/© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NCthat activates myocardial ATPase and strengthens cardiac myosin
cross-bridge formation, resulting in improved heart contraction and
stroke volume without affecting oxygen consumption, heart rate or
blood pressure. COSMIC-HF, the phase 2 clinical trial of oral omecamtiv
mecarbil in patients with HF, is currently recruiting patients, and pre-
liminary results are expected to become available later this year.
Stem cells are natural healers to tissue injuries, and the possibility of
using stem cells as a therapeutic modality is a focus of active research in
regenerative medicine. There have been many clinical trials assessing
the use of stem cells in HF treatment, alone or in conjunctionwith phar-
macotherapies, but results to date are not conclusive. More basic in-
sights are needed to elucidate why not all HF patients respond to stem
cell therapy and what can be done to enhance the effectiveness of this
promising approach to repair a failing heart.
More recently, preliminary data have emerged suggestingmicroRNAs
(miRNAs) as a new potential therapeutic target for HF. High-throughput
screening techniques reveal a dysregulated miRNA proﬁle in HF patients
and identifymicroRNAcandidates for targeted therapyusing antisense ol-
igonucleotides. Encouraging results have been observed in animalmodels
of HF; but it remains to be seen how theﬁndings translate in real patients,
as HF is a multifactorial and complex disease. One of the major obstacles
in human studies involving anti-miRNAs as therapeutics is how to deliver
short fragile oligonucleotides to the siteswhere their action is needed. The
success of therapeutic anti-miRNAs most likely relies on novel effective
delivery systems that can work in patients.
Cardiovascular diseases are a leading cause of death worldwide, af-
fecting both men and women of all ages and ethnic backgrounds, and
putting a heavy burden on healthcare systems. Cardiovascular diseases
are intrinsically intertwined with many other health conditions such as
obesity, diabetes, stroke, dyslipidemia, hypertension, and kidney dis-
ease. One condition can trigger the development of another which in
turns serves as a risk factor for another, and many of these conditions
can be asymptomatic in a large proportion of carriers. Enormous
research efforts resulting in targeted therapies and interventional de-
vices have signiﬁcantly improved the prognosis of many cardiovascular
diseases, but this leads to a paradox when it comes to HF. Many survi-
vors from heart diseases such as acute coronary syndrome, myocardial
infarction and valvular diseases eventually develop HF. HF patients
can also suffer from signiﬁcant comorbidities including renal dysfunc-
tion, respiratory disorder, depression, anemia, and diabetes. Unless
major breakthroughs in HF therapeutics are achieved soon – both in
basic understanding of underlying mechanisms and in clinical testing
of new targeted therapies – HF can become a real healthcare burden
for the next several decades. Successful managements of cardiovascular
conditions rely on an effective interdisciplinary approach to tackle sev-
eral interlinked diseases simultaneously.
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